Halozyme Loses Bid To Protect Breast Cancer Drugs
A London judge on Monday rejected Halozyme's bid to protect an active ingredient in two breast cancer drugs with a supplementary protection certificate, after finding that it was actually an inactive...To view the full article, register now.
Already a subscriber? Click here to view full article